CG Oncology (CGON) and The Competition Head to Head Analysis

CG Oncology (NASDAQ:CGON) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare CG Oncology to related companies based on the strength of its dividends, analyst recommendations, risk, valuation, profitability, earnings and institutional ownership.

Volatility and Risk

CG Oncology has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, CG Oncology’s peers have a beta of -4.48, suggesting that their average share price is 548% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for CG Oncology and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0	1	9	1	3.00
CG Oncology Competitors	1973	5466	14073	305	2.58

CG Oncology presently has a consensus price target of $59.56, suggesting a potential upside of 114.69%. As a group, “Biological products, except diagnostic” companies have a potential upside of 118.01%. Given CG Oncology’s peers higher probable upside, analysts clearly believe CG Oncology has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares CG Oncology and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CG Oncology	$1.14 million	-$48.61 million	-19.54
CG Oncology Competitors	$575.26 million	-$70.96 million	-2.05

CG Oncology’s peers have higher revenue, but lower earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares CG Oncology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	-10,642.98%	-18.97%	-15.36%
CG Oncology Competitors	-2,185.76%	-161.46%	-40.62%

Insider and Institutional Ownership

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

CG Oncology beats its peers on 7 of the 13 factors compared.

CG Oncology Company Profile

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.